View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Nivolumab 1 / Ipilimumab 3 - Nivolumab 240, Melanoma, Malignant, maintenance
Protocol-ID: 713 V2.1 (Mini), NIVO1/IPIL3 - NIVO240, Melanoma, maint.Indication(s)
- Melanoma, Malignant; ICD-10 C44.-
Links
- Nivolumab (opdivo) [EMA EPAR]
- Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing [URL]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 29.01.2023